a Janssen Pharma Kabushiki Kaisha , Health Economics , Chiyoda-ku , Japan.
b Heinrich-Heine-Universitat Dusseldorf Wirtschaftswissenschaftliche Fakultat , Dusseldorf , Germany.
Curr Med Res Opin. 2018 Oct;34(10):1855-1860. doi: 10.1080/03007995.2018.1462782. Epub 2018 May 9.
The objective was to assess the burden of chemotherapy for castration-resistant prostate cancer (CRPC) in Japan.
Utilizing a large administrative hospital database we compared a set of outcome measures 12 months before and after initiation of chemotherapy, namely total medical costs, number of outpatient visits, number of hospital admissions and number of days spent in hospital.
A total of 598 CRPC patients were identified in the database. Total healthcare costs increased from 143,578 Japanese Yen (JPY) per patient per month (PPPM), before chemotherapy, to 333,628 JPY after start of chemotherapy. The number of hospital admissions increased by 280%, and the number of days spent in hospital by 380%.
The overall costs of chemotherapy for patients diagnosed with castration-resistant prostate cancer in Japan are high. Our findings can serve as a basis for health economic evaluations.
评估日本去势抵抗性前列腺癌（CRPC）化疗负担。
利用大型行政医院数据库，我们比较了化疗开始前和开始后 12 个月的一系列结局指标，包括总医疗费用、门诊就诊次数、住院次数和住院天数。
数据库中共确定了 598 例 CRPC 患者。化疗前每位患者每月的总医疗保健费用为 143578 日元（JPY），化疗后增至 333628 JPY。住院次数增加了 280%，住院天数增加了 380%。
日本诊断为去势抵抗性前列腺癌患者的化疗总体成本较高。我们的研究结果可以为卫生经济学评估提供依据。
